Your browser doesn't support javascript.
loading
Tapentadol, the new kid on the block in India: Is it time to worry?
Basu, Debasish; Mahintamini, Tathagata; Ghosh, Abhishek; Roub, Fazle; Subodh, B N; Mattoo, S K; Avasthi, Ajit.
Afiliação
  • Basu D; Department of Psychiatry, Drug De-Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Mahintamini T; Department of Psychiatry, Drug De-Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Ghosh A; Department of Psychiatry, Drug De-Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Roub F; Department of Psychiatry, Drug De-Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Subodh BN; Department of Psychiatry, Drug De-Addiction and Treatment Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Mattoo SK; Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Avasthi A; Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Psychiatry ; 62(6): 697-702, 2020.
Article em En | MEDLINE | ID: mdl-33896976
ABSTRACT
BACKGROUND AND

OBJECTIVES:

Large-scale prospective case series of tapentadol abuse or dependence in India is not available. Hence, we aimed to study the prevalence and profile of tapentadol users in a treatment-seeking population. MATERIALS AND

METHODS:

The study had prospective and retrospective arms. We collected 8-month prospective data by face-to-face interviews (n = 70) and 8-year retrospective data from case notes (n = 26) with either tapentadol misuse/abuse or dependence in patients attending a de-addiction center.

RESULTS:

The prevalence of tapentadol abuse or dependence was 25% among the pharmaceutical opioid users. Concurrent use of other opioids was seen in >80% of participants of both the arms. Major sources of tapentadol were chemists (without a prescription) (53%) and doctors (prescriptions) (40%). Patients in the tapentadol dependence group had a significantly higher dose, duration, and pharmaceutical opioid use.

CONCLUSION:

India needs awareness promotion, training, availability restriction, and provision of treatment for tapentadol abuse or dependence.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Qualitative_research / Risk_factors_studies Idioma: En Revista: Indian J Psychiatry Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Qualitative_research / Risk_factors_studies Idioma: En Revista: Indian J Psychiatry Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Índia
...